FDA panel backs approval of Durata's skin-infection treatment

04/2/2014 | Healio (free registration)

A panel of FDA advisers recommended the approval of Durata Therapeutics' dalbavancin as a treatment for acute bacterial skin infections and skin structure infections, saying the drug showed substantial evidence of safety and efficacy. The drug, however, should not be used in children until further studies are complete, the panel said.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC